Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy

Xianghua Zeng; Shicong Zhu; Cheng Xu; Zhongyu Wang; Xingxing Su; Dong Zeng; Haixia Long; Bo Zhu

doi:10.12659/MSM.922576

07 September 2020 : Clinical Research

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy

Xianghua Zeng^123CDEG, Shicong Zhu^12BCD, Cheng Xu^4CF, Zhongyu Wang^12CD, Xingxing Su^12CD, Dong Zeng^12CD, Haixia Long^12AF*, Bo Zhu^12AG

DOI: 10.12659/MSM.922576

Med Sci Monit 2020; 26:e922576

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 Kaplan-Meier plots of PFS in patients with non-small cell lung cancer undergoing PD1 inhibitors based on comorbidity conditions assessed by Charlson comorbidity index (A) and simplified comorbidity score (B). HR – hazard ratio; CI – confidence interval; PFS – progression-free survival.

Back to the Article

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy

Your Privacy